A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans

Journal of Hypertension

Volumn 30, Issue 4, 2012, Pages 819-827

  Wagner, Frank ^a   Malice, Marie Pierre ^b   Wiegert, Erol ^a   McGrath, Helen E ^c   Gildea, John ^c   Mitta, Shabri ^d   Van Dyck, Kristien ^b   De Lepeleire, Inge ^d   Johnson Levonas, Amy O ^d   Sisk, Christine McCrary ^d   Fernandez, Rose ^d   Greenwalt, Danielle M ^d   Beals, Chan ^d   Carey, Robert M ^c   Nunes, Irene ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MSD Europe   (Belgium)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cicletanine; diuretic; hydrochlorothiazide; kaliuresis; natriuresis

Indexed keywords

CALCIUM; CHLORIDE; CICLETANINE; G PROTEIN COUPLED RECEPTOR KINASE 4; HYDROCHLOROTHIAZIDE; MAGNESIUM; PHOSPHATE; PLACEBO; POTASSIUM; SODIUM;

ADULT; AGED; ALLELE; ARTICLE; CALCIUM EXCRETION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG URINE LEVEL; ELECTROLYTE URINE LEVEL; GENETIC VARIABILITY; HUMAN; HYPERTENSION; KALIURESIS; MAGNESIUM EXCRETION; MALE; NATRIURESIS; PHOSPHATE EXCRETION; POTASSIUM EXCRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SODIUM EXCRETION; URINARY EXCRETION;

EID: 84858702707     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835022a8     Document Type: Article

References (37)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572. (Pubitemid 37430158)
2. Hajjar I, Kotchen JM, Kotchen TA. Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health 2006; 27:465-490.
3. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289:2363-2369. (Pubitemid 37430168)
4. Felder RA, Jose PA. Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity. Nat Clin Pract Nephrol 2006; 2:637-650. (Pubitemid 44655641)
5. Ellison DH, Velazquez H, Wright FS. Thiazide-sensitive sodium chloride cotransport in early distal tubule. Am J Physiol 1987; 253:F546-F554.
6. Greger R. Physiology of renal sodium transport. Am J Med Sci 2000; 319:51-62. (Pubitemid 30367874)
7. Reyes AJ. Diuretics in the therapy of hypertension. J Hum Hypertens 2002; 16 (Suppl 1):S78-S83. (Pubitemid 34449669)
8. Dupont AG. The place of diuretics in the treatment of hypertension: a historical review of classical experience over 30 years. Cardiovasc Drugs Ther 1993; 7 (Suppl 1):55-62. (Pubitemid 23113599)
9. Grobbee DE, Hoes AW. Nonpotassium-sparing diuretics and risk of sudden cardiac death. J Hypertens 1995; 13:1539-1545. (Pubitemid 26015772)
10. McKenney JM, Goodman RP, Wright JT Jr, Rifai N, Aycock DG, King ME. The effect of low-dose hydrochlorothiazide on blood pressure, serum potassium, and lipoproteins. Pharmacotherapy 1986; 6:179-184. (Pubitemid 17204480)
11. Reyes AJ, Taylor SH. Diuretics in cardiovascular therapy: the new clinicopharmacological bases that matter. Cardiovasc Drugs Ther 1999; 13:371-398. (Pubitemid 29472105)
12. Sackner MA, Davidson WD, Sandberg H, Feinberg LJ, Bellet S. Production of potassium depletion by benzothiadiazine compounds. Am J Cardiol 1962; 9:189-193.
13. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35:1025-1030. (Pubitemid 30327250)
14. Gennari FJ. Hypokalemia. N Engl J Med 1998; 339:451-458. (Pubitemid 28377688)
15. Hoskote SS, Joshi SR, Ghosh AK. Disorders of potassium homeostasis: pathophysiology and management. J Assoc Physicians India 2008; 56:685-693.
16. Kalinowski L, Szczepanska-Konkel M, Jankowski M, Angielski S. Cicletanine: new insights into its pharmacological actions. Gen Pharmacol 1999; 33:7-16. (Pubitemid 29292426)
17. Tarrade T, Guinot P. Efficacy and tolerance of cicletanine, a new antihypertensive agent: overview of 1226 treated patients. Drugs Exp Clin Res 1988; 14:205-214.
18. Tarrade T, Berthet P, Paillasseur JL, Bosquet D, Allard M. Antihypertensive effectiveness and tolerance of cicletanine. Results obtained with monotherapy in a large population. Arch Mal Coeur Vaiss 1989; 82(Spec No 4):91-97. (Pubitemid 20003847)
19. Garay RP, Rosati C, Fanous K, Allard M, Morin E, Lamiable D, et al. Evidence for ( +)-cicletanine sulfate as an active natriuretic metabolite of cicletanine in the rat. Eur J Pharmacol 1995; 274:175-180.
20. Franson KL, Kuk JM, Lam NP, Lau AH. Gender effect on diuretic response to hydrochlorothiazide and furosemide. Int J Clin Pharmacol Ther 1996; 34:101-105. (Pubitemid 26079069)
21. Lohmueller KE, Wong LJ, Mauney MM, Jiang L, Felder RA, Jose PA, et al. Patterns of genetic variation in the hypertension candidate gene GRK4: ethnic variation and haplotype structure. Ann Hum Genet 2006; 70:27-41. (Pubitemid 43355559)
22. Sanada H, Yatabe J, Midorikawa S, Hashimoto S, Watanabe T, Moore JH, et al. Single-nucleotide polymorphisms for diagnosis of salt-sensitive hypertension. Clin Chem 2006; 52:352-360.
23. Speirs HJ, Katyk K, Kumar NN, Benjafield AV, Wang WY, Morris BJ. Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension. J Hypertens 2004; 22:931-936. (Pubitemid 38680467)
24. Breslow NE, Clayton DJ. Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993; 88:9-25.
25. Fodor GP, Guinot P. Review of three studies to determine the efficacy and tolerance of cicletanine in the short-and long-term treatment of essential hypertension. Drugs Exp Clin Res 1988; 14:195-204.
26. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248:1465-1477.
27. Rose BD, Tinka LA. Diuretics. In: Kaplan NB, Brenner BM, Laragh JH, editors. The kidney in hypertension. New York: Raven Press; 1987. pp. 179-196.
28. Velazquez H, Wright FS. Control by drugs of renal potassium handling. Annu Rev Pharmacol Toxicol 1986; 26:293-309. (Pubitemid 16090964)
29. Hebert PR, Coffey CS, Byrne DW, Scott TA, Fagard RH, Rottman JN, et al. Treatment of elderly hypertensive patients with epithelial sodium channel inhibitors combined with a thiazide diuretic reduces coronary mortality and sudden cardiac death. J Am Soc Hypertens 2008; 2:355-365.
30. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10-24. (Pubitemid 30367871)
31. Leary WP, Reyes AJ. Diuretics, magnesium, potassium and sodium. S Afr Med J 1982; 61:279-280. (Pubitemid 12139940)
32. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975-978. (Pubitemid 20144223)
33. Ellison DH. Divalent cation transport by the distal nephron: insights from Bartter's and Gitelman's syndromes. Am J Physiol Renal Physiol 2000; 279:F616-F625.
34. Friedman PA. Mechanisms of renal calcium transport. Exp Nephrol 2000; 8:343-350.
35. Gesek FA, Friedman PA. Mechanism of calcium transport stimulated by chlorothiazide in mouse distal convoluted tubule cells. J Clin Invest 1992; 90:429-438.
36. Reusz GS, Dobos M, Tulassay T, Miltenyi M. Hydrochlorothiazide treatment of children with hypercalciuria: effects and side effects. Pediatr Nephrol 1993; 7:699-702. (Pubitemid 24010756)
37. Jounela AJ, Lilja M, Lumme J, Morlin C, Hoyem A, Wessel-Aas T, et al. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press 1994; 3:231-235. (Pubitemid 24257770)